OBJECTIVES: To assess the survival, demography, utilization, and cost patterns of prostate cancer patients in the U.S. veteran population. METHODS: A retrospective database analysis was performed using the Veterans Health Administration (VHA) Medical SAS Datasets from October 1, 2007 to September 30, 2011. All U.S. veteran beneficiaries diagnosed with prostate cancer were identified using International Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis code 185.xx. Survival was determined with the PROC LIFETEST procedure, and descriptive statistics were calculated as means ± standard deviation (SD) and percentages to measure demographic, cost, and utilization distribution in the sample.  RESULTS: Among all study patients diagnosed with prostate cancer (n=222,467), the total survival rate reached 68.24% for patients age  ≤39, 95.76% for those age 40-64, and  88.71% for those age ≥65 years. Patients most frequently resided in the southern parts of the United States (34.85%) and the most common comorbidities were hypertension (n=131,790, 59.24%) and any tumor or other malignancy (n=106,803, 48.01%). The average number of inpatient (0.18, SD=0.67), emergency room (ER) (0.07, SD=0.45), physician office (12.86, SD=14.52) and outpatient visits (13.73, SD=15.30) were calculated for prostate cancer patients. Percentages of inpatient (10.78%), ER (4.10%), physician office (99.89%), and outpatient visits (99.91%) were also calculated. Patient expenditures were found to be $3,721 (SD=$22,184) for inpatient, $18 (SD=$175) for ER, $5,012 (SD=$8,693) for physician office and $5,385 (SD=$9,417) for outpatient visits. CONCLUSIONS: The study suggests that the total survival rate was considerably lower for the youngest age stratum of prostate cancer veterans. However, more research is necessary to better understand adverse events and side effects.